Corcept Therapeutics (CORT) director adds 100,000 shares in open-market buys

Rhea-AI Filing Summary

Corcept Therapeutics director Leonard G. Baker Jr. reported buying a total of 100,000 shares of Common Stock in open-market transactions on March 17, 2026. The purchases were split between 75,782 shares at a weighted average price of $33.0022 and 24,218 shares at a weighted average price of $33.5633, with actual trade prices ranging from $32.43 to $33.68.

Following these purchases, Baker directly holds 1,146,631 Corcept shares. He also has indirect interests in 3,308,303 shares held by a limited partnership and 1,095,262 shares held by a trust, while disclaiming beneficial ownership except to the extent of his pecuniary interests.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BAKER G LEONARD JR

(Last) (First) (Middle)

755 PAGE MILL ROAD

SUITE A-200

(Street)

PALO ALTO CALIFORNIA 94304-1005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		P		75,782	A	$33.0022(1)	1,122,413	D
Common Stock	03/17/2026		P		24,218	A	$33.5633(2)	1,146,631	D
Common Stock								3,308,303	I	By Ltd Partnership(3)
Common Stock								1,095,262	I	By Trust(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $32.43 to $33.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $33.44 to $33.68 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

3. Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

4. Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust.

	/s/ Kanwalpreet S. Kalra, by power of attorney	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Corcept Therapeutics (CORT) director Leonard G. Baker Jr. report in this Form 4?

Leonard G. Baker Jr. reported open-market purchases of Corcept Therapeutics Common Stock totaling 100,000 shares on March 17, 2026. The filing also updates his post-transaction direct and indirect share holdings in the company.

How many Corcept Therapeutics (CORT) shares did the director buy and at what prices?

He bought 75,782 shares at a weighted average price of $33.0022 and 24,218 shares at a weighted average price of $33.5633. Individual trades occurred between $32.43 and $33.68 per share.

How many Corcept Therapeutics (CORT) shares does Leonard G. Baker Jr. own after these purchases?

After the transactions, he directly owns 1,146,631 Corcept shares. The filing also shows indirect holdings of 3,308,303 shares via a limited partnership and 1,095,262 shares via a trust.

Are the reported Corcept Therapeutics (CORT) share prices exact trade prices?

No. The reported prices are weighted averages. Footnotes state the 75,782-share block traded between $32.43 and $33.30, and the 24,218-share block traded between $33.44 and $33.68, with full details available on request.

How are Leonard G. Baker Jr.’s indirect Corcept (CORT) holdings structured?

Indirect holdings include shares held by a limited partnership and a trust where he serves as trustee. He disclaims beneficial ownership of those shares except to the extent of his pecuniary interests in the entities.

Does this Corcept Therapeutics (CORT) Form 4 include any stock option exercises or derivative transactions?

No. The Form 4 only reports non-derivative Common Stock transactions and updated holdings. The derivative section shows no option exercises or other derivative activities associated with this reporting date.